Lysogene delays Sanfilippo gene therapy phase 3 – FierceBiotech
FierceBiotech |
Lysogene delays Sanfilippo gene therapy phase 3
FierceBiotech A manufacturing delay has pushed back the start of Lysogene's pivotal Sanfilippo syndrome trial. The gene therapy study is now due to get underway in the second half of the year. Paris, France-based Lysogene wrapped up preclinical toxicology work on … Lysogene Reports First Quarter Financial Results and Provides Business Update Gene Therapy Market | Industry Outlook Research Report Till 2024 By decisionDatabases Global PharmaSphere: Emerging Biotechnologies-Gene Therapy Market 2018 Review- AnGes MG, Advantagene and … |
